The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway
- Allergy Asthma Clin Immunol. 2022 Feb 17;18(1):12. doi: 10.1186/s13223-022-00652-8.
- 1. Department of Respiratory, Shanghai Ninth People's Hospital Affiliated Shanghai JiaoTong University School of Medicine, No.639, Zhizaoju Road, Shanghai, 200001, China.
- 2. Department of Thoracic Surgery, Shanghai Ninth People's Hospital Affiliated Shanghai JiaoTong University School of Medicine, No.639, Zhizaoju Road, Shanghai, 200001, China. [email protected].
- 3. Department of Respiratory, Shanghai Ninth People's Hospital Affiliated Shanghai JiaoTong University School of Medicine, No.639, Zhizaoju Road, Shanghai, 200001, China. [email protected].
- # Contributed equally.
Background: Epidemiological studies have revealed a link between atopic dermatitis (AD) and asthma. AS1517499, a selective signal transducer and activation of transcription 6 (STAT6) inhibitor, has been shown to effectively block this connection. In this study, we further explored the underlying mechanism by constructing an AD mouse model.
Methods: Female BALB/c mice were randomly divided into four groups (n = 10/group). The AD mouse model was established by 2,4-dinitrochlorobenzene induction with repeated ovalbumin challenge. AS1517499 and corn oil were used as treatment interventions. The features of airway inflammation, remodeling, and hyperactivity were analyzed.
Results: Active use of AS1517499 in AD mice effectively reduced Th2-related cytokine levels, alleviated airway eosinophil and lymphocyte infiltration, and regulated GATA3/Foxp3 levels and subepithelial Collagen deposition. These changes might be due to specific blockade of the STAT6 signaling pathway.
Conclusion: AS1517499 could partially block the association between AD and asthma by specifically inhibiting the STAT6 signaling pathway.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: STAT